Journal of Nephrology and Renal Transplantation is a Quarterly. It attempts to focus on timely and rapid publication of relevant research results in the field of nephrological research. The journal also accepts critical reviews of books and highly cited journal articles. All accepted articles are published electronically ahead of print with the definite citation line; therefore, each article will be available online before official print.
Suggestions for special issues are welcome. To propose a special issue, a one-page proposal should be submitted to the Editor-in-Chief, containing the following information: title; purpose; scope; a list of potential contributors and tentative paper titles; time-table (submission and review deadlines, intended publication date); and guest editor's address, phone, fax and e-mail address. Once approved, the guest editor will be fully responsible for the special issue and should follow the normal review procedure. The guest editor will receive an honorarium.
CFP - Special Issue of JNRT: Resistance to recombinant human erythropoietin therapy in haemodialysis patients
Anaemia is a common complication in haemodialysis patients, resulting in a significant mortality and morbidity in these patients. This anaemia is associated to a decreased bone marrow production of erythrocyte, due to the inability of the failing kidneys to secrete erythropoietin (EPO). The introduction of recombinant human EPO (rhEPO) therapy led to a significant reduction in anemia and improved patients’ quality of life. However, there is a marked variability in the sensitivity to rhEPO, with up to 10-fold variability in dose requirements to achieve correction of anemia. Approximately 5-10% of the patients show a marked resistance to rhEPO therapy.
This variability in the response to rhEPO therapy remains relatively unexplained. rhEPO resistance is associated with several condition. However exclusion of these factors does not eliminate the marked variability in the sensitivity to rhEPO therapy.
Resistance to rhEPO therapy is an important difficulty in the approach of some haemodialysis patients,
Florian Krizanic, Mario Traut, Jens Gerth, Gunter Wolf
54-65
Resistance to recombinant human erythropoietin therapy in haemodialysis patients – focus on inflammatory cytokines, leukocyte activation, iron status and erythrocyte damage
